CRESCENT BIOPHARMA, INC.
No enriched coverage for $CBIO in the last 7 days.
Crescent Biopharma (CBIO) presented its oncology strategy at the Morgan Stanley conference, focusing on CR-001, a PD-1/VEGF bispecific. The company reported $305M in cash, a runway into 2H 2028, and expects key data in Q1 2027. Shares closed at $19.68, up 1.39%, with a market cap of $849.6M and a 66% YTD return. Management acknowledged clinical development risks and potential overvaluation.
Crescent Biopharma (CBIO) will present at two healthcare conferences in September 2026. The company's clinical pipeline includes CR-001, CR-002, and CR-003. Key milestones include ASCEND trial data in 2027 and an IND application for CR-002 in mid-2026. Q2 2026 net loss was $24.8 million. Wedbush maintains an Outperform rating and $27 price target. CBIO stock is down 1.22% at $20.63.
CRESCENT BIOPHARMA, INC. (CBIO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Crescent Biopharma Reports Second Quarter 2026 Financial Results and Recent Business Highlights Enrollment progressing in ASCEND Phase 1/2 global clinical trial evaluating CR-001, a PD-1 x VEGF bispecific antibody, in multiple solid tumor types in first-line and previously treate
Recent CBIO coverage spans financial news, earnings and insider activity.
In the last 30 days, CBIO insiders filed 9 SEC Form 4 transactions — no purchases and 9 sales ($286K). The most active reporter was McNeill Jonathan, President and COO, with 2 filings. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.
The update reinforces the company's long‑run cash position and upcoming data readouts, but no immediate catalyst.
Upcoming conference exposure and data timelines may drive short-term interest.
Clinical execution updates plus a $143.7M public offering extend cash runway into 2H 2028, supporting risk-on positioning into 2027 readouts.
This is a large insider-related fund purchase, but it is indirect and not a 10b5-1 plan, so it may signal conviction without guaranteeing near-term fundamentals.
The announcement signals near-term dilution risk and potential balance-sheet funding, which can pressure the stock until pricing and use of proceeds are clear.
AlphAI scores every news story that mentions CBIO with an AI model for sentiment and relevance, and aggregates insider trades from CRESCENT BIOPHARMA, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Crescent Biopharma (CBIO) presented its oncology strategy at the Morgan Stanley conference, focusing on CR-001, a PD-1/VEGF bispecific. The company reported $305M in cash, a runway into 2H 2028, and expects key data in Q1 2027. Shares closed at $19.68, up 1.39%, with a market cap of $849.6M and a 66% YTD return. Management acknowledged clinical development risks and potential overvaluation.
1 min readCrescent Biopharma (CBIO) will present at two healthcare conferences in September 2026. The company's clinical pipeline includes CR-001, CR-002, and CR-003. Key milestones include ASCEND trial data in 2027 and an IND application for CR-002 in mid-2026. Q2 2026 net loss was $24.8 million. Wedbush maintains an Outperform rating and $27 price target. CBIO stock is down 1.22% at $20.63.
2 min readCRESCENT BIOPHARMA, INC. (CBIO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Crescent Biopharma Reports Second Quarter 2026 Financial Results and Recent Business Highlights Enrollment progressing in ASCEND Phase 1/2 global clinical trial evaluating CR-001, a PD-1 x VEGF bispecific antibody, in multiple solid tumor types in first-line and previously treate
4 min readFairmount Funds Management LLC purchased 853,450 indirectly-held shares of CRESCENT BIOPHARMA, INC. (CBIO) at $14.50 ($12.38M total) on 2026-07-16.
2 min readCrescent Biopharma (Nasdaq: CBIO) began an underwritten public offering of ordinary shares, or pre-funded warrants in lieu of shares, under an SEC shelf registration effective July 10, 2026. The underwriters may buy an additional 15% of shares within 30 days. Jefferies, TD Cowen, Guggenheim and Cantor are joint managers.
2 min readCRESCENT BIOPHARMA, INC. (CBIO) filed an SEC Form 8-K — Results of Operations and Financial Condition. cbio-20260714 0001253689 false 0001253689 2026-07-14 2026-07-14 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ________________________________________________________________________________________________ FORM 8-K ______________________________________
1 min readBrumm Joshua T (Chief Executive Officer) sold 42,305 shares of CRESCENT BIOPHARMA, INC. (CBIO) at $17.99 ($0.76M total) on 2026-06-22 under a Rule 10b5-1 trading plan.
2 min readTang Capital Management, LLC and related entities have disclosed a beneficial ownership of 1,160,000 Ordinary Shares in Crescent Biopharma (CBIO), representing 4.21% of the company's outstanding shares. This information was reported in an amended Schedule 13G/A SEC filing, indicating shared voting and dispositive power among the Tang Capital entities and Kevin Tang. The filing specifies that the percentage is calculated based on 27,571,935 Ordinary Shares outstanding as of April 7, 2026.
2 min readCrescent Biopharma, Inc. (Nasdaq: CBIO) announced it will present at two investor conferences in March 2026: the TD Cowen 46th Annual Health Care Conference and the Leerink Partners 2026 Global Healthcare Conference. The company, a clinical-stage biotechnology firm focused on cancer therapies, will provide live webcasts and replays of these presentations on its investor relations website.
2 min readCrescent Biopharma, Inc. (CBIO) has announced the advancement of its CR-001 cancer trial into the first-in-human stage with a Phase 1/2 study. The trial aims to evaluate the safety, pharmacokinetics, pharmacodynamics, and antitumor activity of CR-001 in adults with locally advanced or metastatic solid tumors. While the study is currently in the "Not Yet Recruiting" phase, this marks a significant value inflection point for the biotech firm, potentially influencing future capital raises or partnerships.
4 min read
